Evidence map›Paper›PMID 38216215›Full record

ArticleActa obstetricia et gynecologica Scandinavica2024

Cancer during pregnancy: Twenty-two years of experience from a tertiary referral center.

Branislav Milosevic, Ivana Likic Ladjevic, Jelena Dotlic, Aleksandra Beleslin, Olga Mihaljevic, Igor Pilic, Vesna Kesic, Miroslava Gojnic, Aleksandar Stefanovic, Katarina Stefanovic

Open access · diamondAbstract read
In one paragraph

Article in Acta obstetricia et gynecologica Scandinavica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Branislav MilosevicClinic for Obstetrics and Gynecology, University Clinical Center of Serbia, Belgrade, Serbia.
Ivana Likic LadjevicClinic for Obstetrics and Gynecology, University Clinical Center of Serbia, Belgrade, Serbia.
Jelena DotlicClinic for Obstetrics and Gynecology, University Clinical Center of Serbia, Belgrade, Serbia.ORCID 0000-0001-9683-9561
Aleksandra BeleslinClinic for Obstetrics and Gynecology, University Clinical Center of Serbia, Belgrade, Serbia.
Olga MihaljevicClinic for Obstetrics and Gynecology, University Clinical Center of Serbia, Belgrade, Serbia.
Igor PilicClinic for Obstetrics and Gynecology, University Clinical Center of Serbia, Belgrade, Serbia.
Vesna KesicClinic for Obstetrics and Gynecology, University Clinical Center of Serbia, Belgrade, Serbia.
Miroslava GojnicClinic for Obstetrics and Gynecology, University Clinical Center of Serbia, Belgrade, Serbia.
Aleksandar StefanovicClinic for Obstetrics and Gynecology, University Clinical Center of Serbia, Belgrade, Serbia.
Katarina StefanovicClinic for Obstetrics and Gynecology, University Clinical Center of Serbia, Belgrade, Serbia.ORCID 0009-0009-4749-3918
University of Belgrade · RSCenter for Health, Exercise and Sport Sciences · RS

Funding

Ministry of Science of the Republic of Serbia 41023/2011
6 · The paper itself

Abstract

introductionCancer complicating pregnancy is a rare but potentially life-threatening condition for both the mother and her child. The aim of the present study was to assess the outcomes for mothers and children after pregnancy complicated by malignancy and to investigate which parameters are important for their 1-year survival. MATERIAL AND

methodsThe study included 84 pregnant women diagnosed with malignant tumors during pregnancy from 2001 to 2022. The pregnancy course and outcome, as well as parameters that could influence the survival and condition of the mother and child were evaluated. Mothers and children were followed up for 1 year after delivery to assess their condition/complications and overall survival.

resultsMost malignancies were gynecological (31%) or hematological (23.8%) and were diagnosed and surgically treated in the second trimester. Most children (69%) showed adequate growth and development throughout pregnancy but were delivered before term (53.6%) to allow mothers to receive therapy. Adjuvant therapy during pregnancy mostly caused a transitory deterioration of the child's condition, while surgery did not significantly impact the pregnancy course. Deliveries, on average, occurred during the 33.01 ± 6.16 gestational week (range: 20-40) and mostly by cesarean section (76.2%). For mothers, the pregnancy survival rate was 95.2% and survival after 1 year was 87.5%. However, 37.5% of women were still ill and required additional therapy 1 year postpartum. The pregnancy survival rate for children was 94%, whereas the 1-year survival rate was 76.2%. Most children had a favorable condition (alive, adequately growing and developing, and without complications) at birth (81%) as well as at the 1-year follow-up (63.7%). Regression analysis identified the following predictors of favorable 1-year maternal condition: applying therapy during pregnancy, no progression of the malignancy during pregnancy, and delivery at a later gestational week. Predictors of favorable 1-year condition of children were lower histopathological grade of malignancy, surgery as therapy for malignancy, obtaining higher birthweight, and delivery by cesarean section.

conclusionsIf the malignancy is not progressing, pregnancy should be continued as long as possible for the child to obtain adequate birthweight. Both surgery and chemotherapy were safe therapeutic choices, as most pregnancies continued successfully after therapy.

Indexed as

Cesarean SectionNeoplasmsBirth WeightChildFemaleHumansInfant, NewbornPostpartum PeriodPregnancyPregnancy OutcomeTertiary Care Centerscancerfollow‐upmother and childpregnancypregnancy outcome

Identifiers

PMID38216215
PMCPMC10993340
OpenAlexW4390810643

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.